Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma

BACKGROUND: The phase 3 CheckMate 649 established superior overall survival of nivolumab in combination with chemotherapy (NIVO + chemo) compared with chemotherapy (chemo) alone as a first-line treatment for patients with Her2-negative advanced gastric cancer, gastroesophageal junction cancer, and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Daniel, Nguyen, Hiep, Shah, Ruchit, Qiao, Yao, Hartman, John, Sugarman, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115724/
https://www.ncbi.nlm.nih.gov/pubmed/36943511
http://dx.doi.org/10.1007/s10120-023-01372-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115724/
https://www.ncbi.nlm.nih.gov/pubmed/36943511
http://dx.doi.org/10.1007/s10120-023-01372-7

Ejemplares similares